Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE)
Guggenheim started coverage on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The firm issued a buy rating and a $19.00 price objective on the stock. Several other equities analysts have also issued reports on MAZE. Leerink Partners initiated coverage on shares of Maze Therapeutics […]
Guggenheim started coverage on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The firm issued a buy rating and a $19.00 price objective on the stock. Several other equities analysts have also issued reports on MAZE. Leerink Partners initiated coverage on shares of Maze Therapeutics […]
